MGNX — MACROGENICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1125345 ·
Last close
$3.96
Market Cap
$251.71M
52W High
$4.64
52W Low
$2.71
ADV30
1,211,987
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,775,000 | 11,245,000 | -33,439,000 | -36,774,000 | 217,873,000 | 66,517,000 | 196,675,000 |
| Dec 2025 | 41,227,000 | 31,112,000 | -12,097,000 | -14,155,000 | 256,846,000 | 57,217,000 | 201,255,000 |
| Sep 2025 | 72,839,000 | 61,250,000 | 18,636,000 | 16,822,000 | 270,763,000 | 80,129,000 | 203,762,000 |
| Jun 2025 | 22,241,000 | 13,335,000 | -36,758,000 | -36,251,000 | 245,416,000 | 130,686,000 | 198,798,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,961,000
Investing CF
$-78,681,000
Financing CF
$69,589,000
CapEx
$-1,729,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.53
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,281,112,000
Inventory
$9,498,000
Receivables
$10,425,000
ST Investments
$87,712,000
EBIT TTM
$-57,725,000
Pretax Income TTM
$-71,030,000
Interest Exp TTM
$13,305,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$157,083,008
EBITDA
$-56,568,000
Free Cash Flow
$10,108,750
Enterprise Value
$133,989,968
Total Cash
$154,228,992
Total Debt
$36,509,000
Shares Out
63,563,123
Trailing EPS
$-1.11
Book Value
$0.33
ROE
-140.3%
ROA
-18.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 149,500,000 | -72,841,000 | -74,620,000 | 256,846,000 | 201,255,000 | — | -81,040,000 |
| Dec 2024 | 149,962,000 | -110,578,000 | -66,966,000 | 261,655,000 | 145,598,000 | — | -68,373,000 |
| Dec 2023 | 58,749,000 | -168,244,000 | -9,058,000 | 298,418,000 | 145,805,000 | — | -78,205,000 |
| Dec 2022 | 150,018,000 | -121,418,000 | -119,758,000 | 280,468,000 | 138,455,000 | — | -86,959,000 |
TTM Snapshot
Revenues TTM
$178,501,000
NetIncome TTM
$-3,836,000
OpCashFlow TTM
$0
Assets (Latest)
$261,655,000
Forward EPS
$-1.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | $250.78M | $6.46 | — |
| AKBA | Akebia Therapeutics, Inc. | $248.14M | $0.93 | — |
| FHTX | Foghorn Therapeutics Inc. | $245.42M | $4.18 | — |
| SLGL | Sol-Gel Technologies Ltd. | $238.33M | $73.44 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $266.95M | $3.75 | — |
News headlines (Yahoo Finance, 1h cache)
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
2026-06-15 16:12 · Yahoo
How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks
2026-06-07 00:18 · Yahoo
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
2026-05-28 22:33 · Yahoo
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
2026-05-28 16:53 · Yahoo
MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates
2026-05-27 10:05 · Yahoo
How The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution Risks
2026-05-22 01:12 · Yahoo
MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are Pretty Bullish On The Stock After Recent Results
2026-05-15 12:54 · Yahoo
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
2026-05-14 20:01 · Yahoo
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
2026-05-13 21:35 · Yahoo
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
2026-05-13 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.